Clinical research is focusing on agents that inhibit IL-1, IL-6, and TNFα pathways to reduce the risk of coronary heart disease and reduce adverse outcomes after injury, which may be potentially useful in COVID-19 treatment, too [29,30,42]. This evidence concerns the gene IL1B and COVID-19.